BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study...
Cancer
MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...
Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial
Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...
BeiGene’s Tislelizumab Shows Promising Results in ESMO Presentations for GC/GEJC and NSCLC
China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced two late-breaking presentations...
BeiGene Submits Supplementary BLA for Tislelizumab in Small Cell Lung Cancer
BeiGene (NASDAQ: BGNE) has announced that its supplementary Biologic License Application (sBLA) for the programmed...
Mabwell to Present Promising Clinical Data at 2023 ESMO Congress
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it will present the...
Ascentage Pharma and AstraZeneca Expand Collaboration on CLL/SLL Treatment
China’s Ascentage Pharma (HKG: 6855) and UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) have entered...
MSD Partners with Phanes Therapeutics for Innovative Cancer Combo Therapy
Global pharmaceutical leader Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic partnership...
Jiangsu Hengrui Licenses Camrelizumab-Apatinib Combo to Elevar Therapeutics
China-based pharmaceutical giant Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has signed a significant licensing...
Kelun-Biotech to Present SKB264 Study Results for Metastatic Breast Cancer at ESMO
China-based pharmaceutical innovator Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its subsidiary Sichuan Kelun-Biotech...
Hainan Poly Pharm’s PL002 Accepted for FDA Review for Liver Cancer Surgery
China-based pharmaceutical company Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that the Investigational...
FDA Approves Pfizer’s Braftovi + Mektovi Combo for BRAF V600E Metastatic NSCLC
The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) regulatory approval for...
Sichuan Huiyu Pharmaceutical’s HYP2090PTSA Gains NMPA Approval for KRAS G12C Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
J&J’s Cetrelimab and TAR-200 Gain Tacit Approvals for Bladder Cancer Trials
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J; NYSE:...
RemeGen Secures NMPA Approval for Phase II Study of Disitamab Vedotin in Breast Cancer
China-based biopharma RemeGen Ltd (HKG: 9995) has announced that it has received approval from the...
Ascentage Pharma Initiates Phase III Study for APG-2575 and Calquence in CLL/SLL
Suzhou-based Ascentage Pharma (HKG: 6855) has announced the approval to commence a global multi-center, randomized,...
Betta Pharmaceuticals Secures NMPA Approval for Befotertinib in NSCLC Treatment
China-based Betta Pharmaceuticals Co., Ltd. (SHE: 300558) has officially announced its receipt of market approval...
MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
Medilink Therapeutics Enters Global Licensing Agreement with BioNTech for HER3-Targeted Antibody Drug Conjugates
Suzhou-based Medilink Therapeutics has announced a strategic cooperation and global licensing agreement with Germany-headquartered BioNTech...
GenFleet Therapeutics’ CDK9 Inhibitor SLS009 Earns Orphan Drug Status for AML
Shanghai-based biotechnology company GenFleet Therapeutics has announced that its CDK9 inhibitor, SLS009 (GFH009), has received...